知微药业科技

Hangzhou Zhiwei Pharmaceutical Technology is a clinical-stage biotechnology company dedicated to the discovery and development of innovative protein degradation therapies. The company utilizes its proprietary platform to develop Proteolysis Targeting Chimeras (PROTACs) and molecular glues aimed at addressing unmet medical needs in oncology and immunology. Its lead candidate, ZW-101, is a potent BTK degrader designed to overcome resistance mechanisms associated with traditional BTK inhibitors in B-cell malignancies. Zhiwei Pharma is supported by prominent venture capital firms and maintains a robust pipeline of early-stage degraders targeting high-value disease drivers.